NASDAQ:VNDAVanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VNDA shares have increased by 8.4% and is now trading at $11.49. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vanda Pharmaceuticals.

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Vanda Pharmaceuticals.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The biopharmaceutical company earned $58 million during the quarter, compared to the consensus estimate of $57.53 million. Vanda Pharmaceuticals had a return on equity of 30.60% and a net margin of 49.12%. View Vanda Pharmaceuticals' earnings history.

Vanda Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $247.77 million.

4 brokerages have issued 12 month price targets for Vanda Pharmaceuticals' shares. Their forecasts range from $12.00 to $25.00. On average, they expect Vanda Pharmaceuticals' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price. View analysts' price targets for Vanda Pharmaceuticals.

News stories about VNDA stock have been trending very negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of -3.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,910,000 shares, an increase of 18.7% from the June 15th total of 4,980,000 shares. Based on an average daily volume of 743,400 shares, the short-interest ratio is presently 7.9 days. Currently, 11.3% of the shares of the company are sold short. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Zogenix (ZGNX), NVIDIA (NVDA), Array Biopharma (ARRY), Micron Technology (MU), Exelixis (EXEL) and ImmunoGen (IMGN).

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include 6 Meridian (0.02%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View institutional ownership trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan, and Timothy Williams. View insider buying and selling activity for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $11.49.

Vanda Pharmaceuticals has a market capitalization of $626.78 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.

The official website for Vanda Pharmaceuticals is www.vandapharma.com.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]